Plain-English translation of NCT06380751 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called saruparib to see if it works better than standard breast cancer treatments for people with advanced hormone receptor-positive breast cancer who carry mutations in the BRCA1, BRCA2, or PALB2 genes. Participants will receive saruparib in combination with other medications, and their results will be compared to people receiving standard treatment options. The goal is to find out which combination works best to slow or stop cancer growth.
People with genetic mutations in BRCA1, BRCA2, or PALB2 genes have breast cancers that may respond differently to treatment. This medication is being tested because it may work particularly well for people with these genetic mutations, potentially offering a better option than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of four treatment combinations—most likely including the new medication saruparib paired with another cancer drug, or a standard treatment combination. You will take oral medication daily and visit your doctor regularly for blood tests, scans, and check-ins to monitor how well the treatment is working and manage any side effects. Treatment continues until your cancer progresses, side effects become unacceptable, or you choose to stop.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States